939 results on '"Juliusson, Gunnar"'
Search Results
2. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
3. Age-specific survival in acute myeloid leukemia in the Nordic countries through a half century
4. High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations
5. Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data
6. The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML
7. Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia
8. Epidemiology and Etiology of AML
9. Hairy cell leukemia and COVID-19 adaptation of treatment guidelines
10. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
11. Pharmacokinetics of Purine Nucleoside Analogs
12. Prospective validation of the prognostic relevance of CD34+CD38– AML stem cell frequency in the HOVON-SAKK132 trial
13. P513: MOLECULAR PATTERN BY AGE AND OVERALL SURVIVAL IN ACUTE MYELOID LEUKEMIA: A POPULATION-BASED STUDY FROM THE SWEDISH AML REGISTRY.
14. P432: VALIDATION OF LIMIT OF QUANTIFICATION APPROACH BASED FLOW CYTOMETRY FOR MEASURABLE RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA IN THE HOVON-SAKK-132 TRIAL
15. P475: EMERGING LEUKEMIA ASSOCIATED IMMUNOPHENOTYPES (LAIPS) IN BONE MARROW OF ACUTE MYELOID LEUKEMIA PATIENTS AFTER INTENSIVE CHEMOTHERAPY.
16. Secondary Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation in a Population-Based Setting
17. Epidemiology and Etiology of AML
18. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia
19. Hairy cell leukemia variant and WHO classification correspondence Re: 5thedition WHO classification haematolymphoid tumors: lymphoid neoplasms
20. Clonal competition within complex evolutionary hierarchies shapes AML over time
21. Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia
22. Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival
23. Figure S2B from Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes
24. Table S1 from Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes
25. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
26. Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival
27. Revisiting coexisting chromosomal abnormalities in NPM1-mutated AML in light of the revised ELN 2022 classification
28. The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML
29. Prospective Validation of CD34+CD38- Leukemic Stem Cell Frequency in the HOVON-SAKK 132 Trial: Perspectives for Future Improvements
30. High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations
31. Measurable Residual Disease Guided Therapy in Intermediate-Risk AML Patients Compared to an Unguided Cohort Using Propensity Score Matching
32. Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations
33. Characterization of therapy-related acute myeloid leukemia : increasing incidence and prognostic implications
34. Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia
35. High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations
36. Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology
37. Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis
38. Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications
39. Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial
40. Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study
41. Venetoclax with intensive chemotherapy in younger patients with acute myeloid leukaemia
42. Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population‐based data from the Swedish Myeloma Register
43. Regional differences in treatment and outcome for myeloma patients in Sweden: A population based Swedish myeloma register study
44. Common Cytogenetic Abnormalities
45. Combinatorial molecule screening identified a novel diterpene and the BET inhibitor CPI-203 as differentiation inducers of primary acute myeloid leukemia cells
46. A risk score based on real-world data to predict early death in acute promyelocytic leukemia
47. IGHV3-21 Gene Frequency in a Swedish Cohort of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia
48. Revisiting coexisting chromosomal abnormalities in NPM1-mutated AML in light of the revised ELN 2022 classification
49. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies
50. Acute myeloid leukemia in the real world: why population-based registries are needed
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.